Core Viewpoint - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price decline [1][2][3]. Financial Performance - For Q1 2025, Integra reported earnings per diluted share of -$0.33, a decline from -$0.04 per diluted share in the same period last year [2]. - The company provided full-year earnings guidance and a second-quarter revenue outlook that fell significantly short of consensus estimates [2]. - Declines were noted in the Neurosurgery and Tissue Technologies segments, attributed to inventory issues and slower ordering patterns [2]. Stock Market Reaction - Following the announcement of the financial results, Integra's stock price dropped by $3.57 per share, or 21.19%, closing at $13.28 per share on May 5, 2025 [3].

LOS ANGELES, May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. As part of its Q1 2025 earnings release, Organon announced it was slashing its quarterly dividend by approximately 90% despite pr ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [2] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [2] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [2] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [2]

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. ("GoHealth" or the "Company") (NASDAQ: GOCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether GoHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2025, the U.S. De ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Wabash National Corporation and its executives [1] Financial Performance - Wabash reported an operating loss of $9.8 million in its Transportation Solutions segment for Q1 2025, a significant decline from an operating profit of $44.25 million in Q1 2024 [2] - The company's gross profit for Q1 2025 was $19 million, down from $76.4 million in Q1 2024 [2] - Wabash revised its annual revenue forecast to approximately $1.8 billion, a decrease from the previous projection of $1.9 billion made in February 2025 [2] Market Reaction - Following the announcement of its financial results, Wabash's stock price dropped by $3.05 per share, or 30.62%, closing at $6.91 per share on April 30, 2025 [3]

Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential securities fraud and unlawful business practices following significant financial losses and a product recall [1][3]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a stark contrast to an adjusted net income of $24 million in Q1 2024 [3]. - The company has revised its full-year growth outlook to a range of 4.5% to 6.5% year-over-year, down from a previous guidance of 5.5% to 7.5% [3]. Stock Price Movement - Following the announcement of a voluntary recall of intraocular lenses due to toxic anterior segment syndrome, Bausch + Lomb's stock price dropped by $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [2]. - After the release of Q1 2025 financial results, the stock price fell further by $2.16 per share, or 15.74%, closing at $11.56 on April 30, 2025 [4].

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  FTI Consulting, Inc. ("FTI" or the "Company") (NYSE: FCN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether FTI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On April 24, 2025, FTI issued a pr ...

Core Viewpoint - Landstar System, Inc. is under investigation for potential securities fraud and unlawful business practices following the disclosure of significant supply chain fraud that may impact its earnings [1][2]. Group 1: Company Financial Impact - On April 2, 2025, Landstar identified a significant supply chain fraud that could adversely affect its first quarter 2025 earnings per share by $0.35 to $0.50, leading to the withdrawal of its previous earnings guidance [2]. - Following this announcement, Landstar's stock price dropped by $13.30, or 8.75%, closing at $138.63 on April 3, 2025 [2]. - On April 25, 2025, Landstar announced it would be unable to file its quarterly report on time due to ongoing evaluations of accounting and internal control matters related to the fraud, resulting in a further stock price decline of $4.92, or 3.52%, to close at $135.00 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Landstar investors regarding potential securities fraud and unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Adverum Biotechnologies, Inc. following the company's announcement of the need to restate its financial statements due to accounting errors [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Adverum and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - The investigation was prompted by Adverum's disclosure that certain previously issued financial statements should no longer be relied upon due to non-cash errors related to tenant improvement allowances [3]. Group 2: Financial Impact - On March 31, 2025, Adverum announced it would restate its financial statements for the years ended December 31, 2022 and 2023, as well as unaudited quarterly financial information for 2023 and 2024 [3]. - Following the announcement, Adverum's stock price dropped by $0.54 per share, representing a decline of 12.36%, closing at $3.83 per share on April 1, 2025 [3]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].